VHH single-domain antibodies are a new frontier in biological therapeutics that traditional E. coli and Chinese Hamster Ovary (CHO) methods have struggled to advance to their full potential.
This case study describes how Phenotypeca, in collaboration with VHH experts Isogenica Ltd, successfully optimised baker’s yeast strains to produce high-quality VHH antibodies for both research and large-scale commercial manufacture.
Challenge
The production of antibody therapeutics, typically using CHO cells, can be costly and inefficient. This limits research and increases medicine prices. The challenge for Phenotypeca and Isogenica, therefore, was to find a more effective and cost-efficient method for developing and manufacturing high-quality VHH therapeutics.
Solution
Phenotypeca used proprietary Quantitative Trait Loci (QTL) technology to enhance the secretion and display of functional VHH proteins on Saccharomyces cerevisiae yeast strains.
Key Outcomes
The new approach achieved a remarkable 10-20 fold increase in the yield of secreted VHH products, without any compromise of quality and bioactivity.
What’s Next?
QTL technology is set to revolutionise recombinant protein manufacturing across a range of applications. This includes the development and production of vaccines, biosimilars, proprietary biologics, and cosmeceuticals. Strains can be customised to meet the specific needs of any given market, while also enhancing patent protection.
Learn more about this exciting new approach by clicking below and downloading the full case study.
Download the case study here – VHH Case Study
